Potential antiviral properties of antiplatelet agents against SARS-CoV-2 infection: an in silico perspective

SARS-CoV-2 represents the causative agent of the current pandemic (COVID-19). The drug repurposing technique is used to search for possible drugs that can bind to SARS-CoV-2 proteins and inhibit viral replication. In this study, the FDA-approved antiplatelets are tested against the main protease and...

Full description

Saved in:
Bibliographic Details
Published in:Journal of thrombosis and thrombolysis 2022-02, Vol.53 (2), p.273-281
Main Authors: Abosheasha, Mohammed A., El-Gowily, Afnan H., Elfiky, Abdo A.
Format: Article
Language:English
Subjects:
Antiviral activity
Antiviral agents
Antiviral Agents - pharmacology
Antiviral drugs
Cardiology
Cilostazol
Coronavirus 3C Proteases - antagonists & inhibitors
Coronaviruses
COVID-19
COVID-19 - drug therapy
Hematology
Humans
Lactones
Medicine
Medicine & Public Health
Molecular Docking Simulation
Molecular dynamics
Molecular Dynamics Simulation
Platelet Aggregation Inhibitors - pharmacology
Proteinase
Pyridines
SARS-CoV-2 - drug effects
Severe acute respiratory syndrome coronavirus 2
Spike Glycoprotein, Coronavirus - antagonists & inhibitors
Spike protein
Ticagrelor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:SARS-CoV-2 represents the causative agent of the current pandemic (COVID-19). The drug repurposing technique is used to search for possible drugs that can bind to SARS-CoV-2 proteins and inhibit viral replication. In this study, the FDA-approved antiplatelets are tested against the main protease and spike proteins of SARS-CoV-2 using in silico methods. Molecular docking and molecular dynamics simulation are used in the current study. The results suggest the effectiveness of vorapaxar, ticagrelor, cilostazol, cangrelor, and prasugrel in binding the main protease (M pro ) of SARS-CoV-2. At the same time, vorapaxar, ticagrelor, and cilostazol are the best binders of the spike protein. Therefore, these compounds could be successful candidates against COVID-19 that need to be tested experimentally.
ISSN:0929-5305
1573-742X
DOI:10.1007/s11239-021-02558-5